Skip to content

Relationship Between Potential Predictors and Mortality in COVID-19 Patients ın Turkey

Relationship Between Potential Predictors and Mortality in COVID-19 Patients in Turkey: A New Prognostic Model

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04789460
Enrollment
816
Registered
2021-03-09
Start date
2021-03-05
Completion date
2021-03-28
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

covid19, ldh, ferritin, mortality, d-dimer

Brief summary

In this study, the investigators planned to examine the laboratory characteristics of patients hospitalized with the diagnosis of Covid-19 and to investigate their relationship with mortality.

Detailed description

SARS-CoV-2 infection is effective in many countries and has caused pandemics. It is observed that it affects patients in a wide spectrum in terms of their clinical features worldwide. It is known that age, gender, and comorbidity play an important role in the course of the disease. Although mortality rates vary from country to country, there is no clear information due to the fact that the pandemic has not yet ended. In this study, the investigators planned to examine the laboratory characteristics of patients hospitalized with the diagnosis of Covid-19 and to investigate their relationship with mortality in Istanbul city which is the most affected by the pandemic in Turkey

Interventions

None listed

Sponsors

Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients who are 18 years of age and older, positive for SARS-CoV-2 PCR test and / or Covid-19 disease findings on CT will be included in the study.

Exclusion criteria

* Patients with negative SARS-CoV-2 PCR test, pneumonia on CT but not given Covid-19 treatment by not considering Covid-19 by their doctor will not be included.

Design outcomes

Primary

MeasureTime frameDescription
mortality rateup to 30 daysup to 30 days after discharge

Secondary

MeasureTime frameDescription
need for intensive care unit rateup to 30 daysneed for intensive care unit during hospitalization
length stay in hospitalup to 30 daysnumber of length stay in hospital

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026